230 related articles for article (PubMed ID: 30741378)
21. Different HLA DR-DQ associations in subgroups of idiopathic myasthenia gravis.
Carlsson B; Wallin J; Pirskanen R; Matell G; Smith CI
Immunogenetics; 1990; 31(5-6):285-90. PubMed ID: 1973409
[TBL] [Abstract][Full Text] [Related]
22. Association of HLA-DQA1*0101/2 and DQB1*0502 with myasthenia gravis in southern Iranian patients.
Yousefipour GA; Salami Z; Farjadian S
Iran J Immunol; 2009 Jun; 6(2):99-102. PubMed ID: 19561379
[TBL] [Abstract][Full Text] [Related]
23. HLA and age of onset in myasthenia gravis.
Santos E; Bettencourt A; da Silva AM; Boleixa D; Lopes D; Brás S; Costa PPE; Lopes C; Gonçalves G; Leite MI; da Silva BM
Neuromuscul Disord; 2017 Jul; 27(7):650-654. PubMed ID: 28495048
[TBL] [Abstract][Full Text] [Related]
24. Response to treatment of myasthenia gravis according to clinical subtype.
Akaishi T; Suzuki Y; Imai T; Tsuda E; Minami N; Nagane Y; Uzawa A; Kawaguchi N; Masuda M; Konno S; Suzuki H; Murai H; Aoki M; Utsugisawa K
BMC Neurol; 2016 Nov; 16(1):225. PubMed ID: 27855632
[TBL] [Abstract][Full Text] [Related]
25. HLA-DQA1*03:02/DQB1*03:03:02 is strongly associated with susceptibility to childhood-onset ocular myasthenia gravis in Southern Han Chinese.
Zhu WH; Lu JH; Lin J; Xi JY; Lu J; Luo SS; Qiao K; Xiao BG; Lu CZ; Zhao CB
J Neuroimmunol; 2012 Jun; 247(1-2):81-5. PubMed ID: 22503410
[TBL] [Abstract][Full Text] [Related]
26. HLA typing using next-generation sequencing for Chinese juvenile- and adult-onset myasthenia gravis patients.
Feng X; Li W; Song J; Liu X; Gu Y; Yan C; Wu H; Xi J; Zhou S; Zhao C
J Clin Neurosci; 2019 Jan; 59():179-184. PubMed ID: 30595166
[TBL] [Abstract][Full Text] [Related]
27. Association of HLA-DQB1∗05:02 and DRB1∗16 Alleles with Late-Onset, Nonthymomatous, AChR-Ab-Positive Myasthenia Gravis.
Testi M; Terracciano C; Guagnano A; Testa G; Marfia GA; Pompeo E; Andreani M; Massa R
Autoimmune Dis; 2012; 2012():541760. PubMed ID: 23091703
[TBL] [Abstract][Full Text] [Related]
28. Two cases of thymoma-associated myasthenia gravis without antibodies to the acetylcholine receptor.
Maggi L; Andreetta F; Antozzi C; Confalonieri P; Cornelio F; Scaioli V; Mantegazza R
Neuromuscul Disord; 2008 Aug; 18(8):678-80. PubMed ID: 18657424
[TBL] [Abstract][Full Text] [Related]
29. Thymoma-associated myasthenia gravis: Clinical features and predictive value of antiacetylcholine receptor antibodies in the risk of recurrence of thymoma.
De Rosa A; Fornili M; Maestri Tassoni M; Guida M; Baglietto L; Petrucci L; Chella A; Melfi F; Lucchi M; Ricciardi R
Thorac Cancer; 2021 Jan; 12(1):106-113. PubMed ID: 33142021
[TBL] [Abstract][Full Text] [Related]
30. Genetic heterogeneity within the HLA region in three distinct clinical subgroups of myasthenia gravis.
Saruhan-Direskeneli G; Hughes T; Yilmaz V; Durmus H; Adler A; Alahgholi-Hajibehzad M; Aysal F; Yentür SP; Akalin MA; Dogan O; Marx A; Gülsen-Parman Y; Oflazer P; Deymeer F; Sawalha AH
Clin Immunol; 2016 May; 166-167():81-8. PubMed ID: 27181991
[TBL] [Abstract][Full Text] [Related]
31. [The significance of Titin antibody in diagnosing myasthenia gravis with thymoma].
Chen X; Lü C; Qiao J
Zhonghua Yi Xue Za Zhi; 2001 Sep; 81(18):1118-20. PubMed ID: 11766610
[TBL] [Abstract][Full Text] [Related]
32. Clinical characteristics and outcomes of thymoma-associated myasthenia gravis.
Álvarez-Velasco R; Gutiérrez-Gutiérrez G; Trujillo JC; Martínez E; Segovia S; Arribas-Velasco M; Fernández G; Paradas C; Vélez-Gómez B; Casasnovas C; Nedkova V; Guerrero-Sola A; Ramos-Fransi A; Martínez-Piñeiro A; Pardo J; Sevilla T; Gómez-Caravaca MT; López de Munain A; Jericó I; Pelayo-Negro AL; Martín MA; Morgado Y; Mendoza MD; Pérez-Pérez H; Rojas-García R; Turon-Sans J; Querol L; Gallardo E; Illa I; Cortés-Vicente E
Eur J Neurol; 2021 Jun; 28(6):2083-2091. PubMed ID: 33721382
[TBL] [Abstract][Full Text] [Related]
33. Myasthenia gravis in individuals over 40.
Aarli JA; Romi F; Skeie GO; Gilhus NE
Ann N Y Acad Sci; 2003 Sep; 998():424-31. PubMed ID: 14592910
[TBL] [Abstract][Full Text] [Related]
34. Postthymectomy myasthenia gravis: relationship with thymoma and antiacetylcholine receptor antibody.
Nakajima J; Murakawa T; Fukami T; Sano A; Takamoto S; Ohtsu H
Ann Thorac Surg; 2008 Sep; 86(3):941-5. PubMed ID: 18721587
[TBL] [Abstract][Full Text] [Related]
35. Clinical and pathologic predictors of outcome in thymoma-associated myasthenia gravis.
López-Cano M; Ponseti-Bosch JM; Espin-Basany E; Sánchez-García JL; Armengol-Carrasco M
Ann Thorac Surg; 2003 Nov; 76(5):1643-9; discussion 1649. PubMed ID: 14602301
[TBL] [Abstract][Full Text] [Related]
36. Correlation of thymic pathology with HLA in myasthenia gravis.
Machens A; Löliger C; Pichlmeier U; Emskötter T; Busch C; Izbicki JR
Clin Immunol; 1999 Jun; 91(3):296-301. PubMed ID: 10370374
[TBL] [Abstract][Full Text] [Related]
37. Antititin antibody in early- and late-onset myasthenia gravis.
Szczudlik P; Szyluk B; Lipowska M; Ryniewicz B; Kubiszewska J; Dutkiewicz M; Gilhus NE; Kostera-Pruszczyk A
Acta Neurol Scand; 2014 Oct; 130(4):229-33. PubMed ID: 24947881
[TBL] [Abstract][Full Text] [Related]
38. Effects of thymectomy on late-onset non-thymomatous myasthenia gravis: systematic review and meta-analysis.
Zhang J; Chen Y; Zhang H; Yang Z; Zhang P
Orphanet J Rare Dis; 2021 May; 16(1):232. PubMed ID: 34016126
[TBL] [Abstract][Full Text] [Related]
39. Gm allotypes in myasthenia gravis.
Nakao Y; Matsumoto H; Miyazaki T; Nishitani H; Ota K; Fujita T; Tsuji K
Lancet; 1980 Mar; 1(8170):677-80. PubMed ID: 6103092
[TBL] [Abstract][Full Text] [Related]
40. Thymoma-associated myasthenia gravis: On the search for a pathogen signature.
Cufi P; Soussan P; Truffault F; Fetouchi R; Robinet M; Fadel E; Berrih-Aknin S; Le Panse R
J Autoimmun; 2014 Aug; 52():29-35. PubMed ID: 24440286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
